A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
Additional file 1: Figure S1. Plasma copeptin by KDIGO eGFR categories and by UAC categories at baseline. Table S1. Clinical characteristics at baseline by tertiles of plasma copeptin. Table S2. Risk of individual cardiovascular outcomes during follow-up by tertiles of plasma copeptin at baseline—DIABHYCAR and SURDIAGENE pooled data. Table S3. Rapid kidney function decline during follow-up by tertiles of plasma copeptin at baseline. Table S4. SURGENE cohort—Kidney outcome during the follow-updoi:10.6084/m9.figshare.6916454 fatcat:ttc3l3hlpvfmpn273hea5epee4